The HSPA2 Knockout A-549 Polyclonal Cells are a heterogeneous CRISPR/Cas9-edited population with targeted disruption of the HSPA2 gene, providing a pooled loss-of-function model for studying HSPA2 ablation in a human lung adenocarcinoma background. This polyclonal format minimizes clonal bias and captures diverse editing outcomes, enabling robust functional genomics and drug target validation studies.
The A-549 cell line, derived from a human lung adenocarcinoma, is a widely used model of type II alveolar epithelial cells. These adherent epithelial cells are central to non-small cell lung cancer (NSCLC) research, oncogenic signaling studies, and therapeutic response profiling. A-549 cells exhibit high tumorigenicity and sensitivity to chemotherapeutics such as cisplatin, making them valuable for drug resistance investigations. Their active MAPK, PI3K/AKT, and stress-response pathways position them as an optimal host for examining the functional contributions of molecular chaperones like HSPA2.
HSPA2 is an ATP-dependent molecular chaperone transcriptionally regulated by heat shock factor 1 (HSF1) and induced by heat shock, oxidative stress, hypoxia, and TNF-??. It collaborates with co-chaperones HOP (STIP1) and HSP40 (DNAJB1) to fold and stabilize client proteins, including steroid receptors and kinases. Through direct interactions, HSPA2 promotes BCL2 and suppresses BAX to inhibit intrinsic apoptosis, while also sustaining prosurvival signaling via AKT and ERK phosphorylation and supporting cell cycle progression through CDK association. The BAG family of co-chaperones modulates its ATPase cycle, tuning its activity within protein processing pathways.
In A-549 cells, HSPA2 is constitutively expressed and supports oncogenic signaling and stress adaptation. Knockout is predicted to impair protein homeostasis, heighten proteotoxic stress, and increase apoptosis sensitivity via the HSF1-HSPA2-BCL2 axis, along with attenuated AKT and ERK pathway activation, reduced cell cycle progression, and lower migratory capacity. Given the A-549 model’s relevance to NSCLC drug resistance, this polyclonal knockout system enables dissection of HSPA2??s role in chemosensitivity and identification of synthetic lethal interactions.
These cells support diverse experimental workflows: western blotting and RT-qPCR for knockout verification; MTT, colony formation, and Annexin V assays to assess proliferation and apoptosis under heat shock or drug stress; Transwell assays for migration/invasion; RNA-seq for transcriptomic profiling; and co-immunoprecipitation to map altered interactomes. The model is particularly useful for drug sensitivity screening (e.g., cisplatin dose responses) and CRISPR-based synthetic lethality screens. For detailed protocols and culture recommendations, please contact Ascent Research.
